Intermittent Hormone Therapy Fails the Test

A very important randomized study is being presented at the ASCO meeting and appears to show that intermittent hormone therapy results in a worse survival in men with metastatic prostate cancer compared to men on continuous therapy. This is consistent with another study done in Europe and it is important for many reasons, most importantly it is another example of the need to do a randomized study to properly evaluate if a treatment is good enough. A full video will be done next week. (June 4, 2012)

Category: In The News

Leave a Reply

You must be logged in to post a comment.